Molecular Neurobiology

, 35:55

Neuroprotection against neurodegenerative diseases

Development of a novel hybrid neuroprotective peptide colivelin
Article

DOI: 10.1007/BF02700624

Cite this article as:
Chiba, T., Nishimoto, I., Aiso, S. et al. Mol Neurobiol (2007) 35: 55. doi:10.1007/BF02700624

Abstract

Neuronal death is directly implicated in the pathogenesis of neurodegenerative diseases (NDDs). NDDs cannot be cured because the mechanisms underlying neuronal death are too complicated to be therapeutically suppressed. Neuroprotective factors, such as neurotrophins, certain growth factors, neurotrophic cytokines, and short neuroprotective peptides, support neuronal survival in both physiological and pathological conditions, suggesting that these factors may be good drug candidates for NDDs. We recently generated a novel neuroprotective peptide named Colivelin by attaching activity-dependent neurotrophic factor (ADNF) to the N-terminus of a potent Humanin derivative, AGA-(C8R)HNG17. HN was originally identified from an Alzheimer’s disease (AD) brain as an endogenous neuroprotective peptide that suppresses AD-relevant toxicity. Colivelin protects neurons from death relevant to NDDs by activating two independent prosurvival signals: an ADNF-mediated Ca2+/calmodulin-dependent protein kinase IV pathway and an HN-mediated STAT3 pathway. The neuroprotective effect of Colivelin provides novel insights into therapy for NDDs.

Index Entries

Colivelin humanin ADNF neuronal death neuroprotection neurodegenerative diseases 

Copyright information

© Humana Press Inc 2007

Authors and Affiliations

  1. 1.Department of Anatomy and PharmacologyKEIO University School of MedicineTokyoJapan

Personalised recommendations